Search this site

Discover our groundbreaking research in Oncology. Explore our publications to see research that matters. Stay informed with our latest insights. Expert Insights Insights that shape the domain Deep-dive into expert opinions, scientific perspectives, and thought leadership shaping the future of cancer care. View more TEDx Talk — Capturing cancer cells-Uncovering secrets for treatments by Aravindan Vasudevan – CEO, Actorius Date: February 28, 2023 TedxTalks Link Regular Information = Actionable Insights Helping the world to become cancer-free

Review the clinical performance of OncoMetastat®, highlighting evidence on circulating tumor cell (CTC) detection and its role in understanding disease progression and metastasis. Data-backed research results. Explore the clinical foundation of OncoMetastat®, highlighting data on circulating tumor cell (CTC) detection, characterization, and their role in understanding metastasis. Book a demo View Technology Analytical Concordance Between OncoMetastat® and OncoDiscover® 17 True Positives 01 False Positives 01 False Negatives 13 True Negatives 94.4 % Sensitivity 92.9 % Specificity 94.4 % PPV (Positive Predictive Value) 92.9 % NPV (Negative Predictive Value) 93.8 % Accuracy 93.7 % Balanced Accuracy OncoDiscover® is a DCGI-approved CTC enumeration assay employing EpCAM immunocapture and CK/CD45/DAPI staining; it served as the internal reference method in this preliminary analytical assessment. Data are from internal studies and has not been reviewed or approved by the U.S. FDA. N=32 CTC Captured by OncoMetastat® Brightfield DAPI CK18 Merge CTCs Captured on OncoMetastat® Platform on the EpCAM/Tf functionalized glass bead. Blood Parameter Testing with OncoMetastat® Evaluation of Potential Hemolysis in OncoMetastat® (OMS) 0.9 % OncoSpiral 0.8 % Glass Beads <2.0 % OMS Device Blood Protein Level Changes During OncoMetastat® Processing 70 mg/m Control Serum 68.96 mg/m Processed Serum 1.5 % Protein Loss to Processing Evaluation of Leucocyte (WBC) Adsorption on OncoMetastat® Beads 2+/-1 WBC Count (Bead-adherent WBCs) OMS Processing 1+/-1 WBC Count (Bead-adherent WBCs) OMS (with Vibration) Evaluation of OncoMetastat® Induced Pyrogenicity 37 °C Body Temperature Control 37+/-0.5 °C Body Temperature OMS References Khandare, et. al. Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient’s whole blood. ASCO 2026 Khandare, et. al. Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates. AACR 2026 Khandare, et. al. Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. J Clin Oncol 2025; 43. Khandare, et. al. Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate. The Journal of Liquid Biopsy 2025; 9; 100334. Khandare, et. al. Extracorporeal microchannel device to capture and eliminate circulating tumor cells from cancer patient’s blood. J Clin Oncol 2022; 40. Khandare, et. al. Device for the enumeration and continuous removal of circulating tumor cells in improving overall survival of epithelial cancer patients. J Clin Oncol 2020; 38.

Access research manuscripts and scientific contributions from Actorius highlighting advances in oncology research, CTC detection, and liquid biopsy technologies. Manuscripts Research That Shapes the Future of Oncology Access studies, scientific papers, and published findings advancing cancer diagnostics and care. 27 Jan 2026 Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... Read More 14 Mar 2025 Manuscript: The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes. Read More 15 Jul 2024 Manuscript: Inverse 3D ‘lab-on-a-chip’ polymeric microfilms for selective capture of circulating tumor cells from patients' blood Inverse 3D lab-on-chip microfilms for selective CTC capture from blood. Read More 29 Jun 2024 Manuscript: Circulating Tumor Cells as Biomarkers for Relapse Detection in Rectal Cancer with Liver Metastasis: Insights from a Case Report In this case report we demonstrate the utility of CTC as a sensitive marker to detect MRD. CTCs play a crucial role in the context of MRD in colorectal cancer, offering a valuable biomarker for prognosis, treatment monitoring, and early detection of recurrence. Read More 4 Apr 2024 Manuscript: CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Study links Shh/Nrf2 overexpression with circulating tumor cells in HNSCC, highlighting their potential as biomarkers for early detection and survival prediction. Read More 20 Sept 2023 Manuscript: Magnetically-activated, nanostructured cellulose for efficient capture of CTCs from the blood sample of head and neck cancer patients Study compares CNC and CNF cellulose nanostructures for EpCAM-based CTC capture in head and neck cancer, enabling affordable real-time cancer monitoring. Read More 20 Jul 2023 Manuscript: Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) This study highlights the utility of CTCs as a disease progression monitoring tool in recurrent HNSCC patients. Our findings suggest the potential clinical utility of CTCs and the need for further exploration in upfront settings of the disease as well (NCT: CTRL/2020/02/023378). Read More 11 Apr 2023 Manuscript: Chemical tunability of advanced materials used in the fabrication of micro/nanobots Review on chemically tunable micro- and nanobots for targeted nanomedicine, highlighting AI materials, applications, and biosafety considerations. Read More 1 Jul 2022 Manuscript: Circulating tumor cells as a predictor for poor prognostic factors and overall survival in treatment nay¨ve oral squamous cell carcinoma patients Preoperative circulating tumor cell levels strongly correlate with metastasis, disease severity, and reduced survival in oral squamous cell carcinoma patients. Read More 27 Apr 2022 Manuscript: Bioinspired Materials for Wearable Devices and Point-of-Care Testing of Cancer Raj Shankar Hazra, Md Rakib Hasan Khan, Narendra Kale, Tabassum Tanha, Jayant Khandare, Sabha Ganai, and Mohiuddin Quadir* Read More 18 Feb 2022 Manuscript: Antibody mediated cotton-archetypal substrate for enumeration of circulating tumor cells and chemotherapy outcome in 3D tumors Cotton microfluidic substrate enables efficient CTC isolation, 3D tumor growth, and drug response testing for improved cancer diagnostics and therapy research. Read More 18 Dec 2020 Manuscript: Chemo-specific designs for the enumeration of circulating tumor cells: advances in liquid biopsy Review on chemo-specific nano/micro substrates for efficient CTC isolation, enabling liquid biopsy, metastasis detection, and real-time cancer monitoring. Read More 10 Oct 2020 Manuscript: Cellulose Mediated Transferrin Nanocages for Enumeration of Circulating Tumor Cells for Head and Neck Cancer Magnetic transferrin-functionalized cellulose nanocages capture circulating tumor cells from blood, enabling liquid biopsy for early metastasis detection in head and neck cancer. Read More 11 Feb 2018 Manuscript: Optimizing Circulating Tumor Cells’ Capture Efficiency of Magnetic Nanogels by Transferrin Decoration Magnetic nanogels with optimized PEG–transferrin linkers achieve over 80% efficiency in selectively capturing circulating tumor cells from blood. Read More 17 Jan 2018 Manuscript: Selective Cell Isolation by Transferrin Functionalized Silane– Carbon Soot Mediated Superhydrophobic Micropatterns Transferrin-functionalized wettability micropatterns enable selective cancer cell capture and real-time monitoring for diagnostics and recurrence detection. Read More 17 Jan 2017 Manuscript: Biofunctionalized Capillary Flow Channel Platform Integrated with 3D Nanostructured Matrix to Capture Circulating Tumor Cells Continuous-flow 3D microchannel platform captures circulating tumor cells with ~90% efficiency, enabling liquid biopsy and real-time cancer monitoring. Read More 17 Apr 2015 Manuscript:Calcium phosphate nanocapsule crowned multiwalled carbon nanotubes for pH triggered intracellular anticancer drug release Calcium phosphate–capped carbon nanotubes enable pH-triggered intracellular release of doxorubicin, preventing premature drug leakage and improving targeted cancer therapy. Read More 13 Apr 2015 Manuscript: Self-propelled Carbon Nanotube Based Microrockets for Rapid Capture and Isolation of Circulating Tumor Cells Self-propelled CNT microrockets rapidly capture and magnetically isolate circulating tumor cells, enabling faster liquid biopsy and early cancer detection. Read More First Prev 1 Page 1 Next Last

Reach out to the OncoMetastat® team for clinical information, partnerships, or inquiries related to metastasis control solutions. Contact Us First name* Last name* Email* Phone* Address Country/Region* Address* City* Zip / Postal code* What are you looking for?* Book a demo Event enquiry Press or Media Enquiry Other Message* Submit We'd love to hear from you Whether it’s research, technology, or partnership opportunities, we’re here to explore what’s next—together. Write to us Our Address Visit Us Here’s where you can reach us in person. We look forward to welcoming you. US office 11842, Churchill Way, Porter Ranch, CA 91326 US Lab Pasadena Bio Collaborative Incubator, 2265 E Foothill Blvd, Pasadena, CA 91107

Explore OncoMetastat® technology designed to capture, analyze, and deplete circulating tumor cells (CTCs), enabling deeper insights into metastasis and cancer progression at the cellular level. The OncoMetastat® Technology OncoMetastat® is built on an advanced approach to capture, study, and deplete circulating tumor cells (CTCs)—the drivers of metastasis. By focusing on tumor cell dynamics in the blood, the platform enables deeper insights into disease progression and supports strategies aimed at delaying cancer metastasis in early stage cancers.. Book a demo View clinical data Core Technology Precision engineering for CTC depletion. OncoMetastat® is an investigational extracorporeal blood-processing platform , inspired by blood-dialysis principles, and envisaged to selectively capture and deplete circulating tumor cells (CTCs) from a patient’s blood while maintaining blood integrity. Designed with a focus on precision and safety , the prototype is currently under evaluation for its potential research relevance to metastasis and broader cancer management. Spiral Filtration System Spiral channel housing CTC-capturing glass beads 3D printed with biomedical grade resin can filter 1-10 ml clinical blood sample. Affinity Based System Ligand-conjugated glass beads designed to capture circulating tumor cells (CTCs) for investigational evaluation. Ligands are EpCAM, Transferrin and N-Cadherin. Biocompatible Design Constructed from non-immunogenic materials to support durability and biocompatibility testing. Built-in Safety Controls Includes provisions for anti-coagulant handling and mixing systems during prototype testing. Continuous Automated Operation Designed to model gentle, continuous and automated blood circulation similar to dialysis principles for investigational use. Algorithmic Image Analysis Use of image processing algorithms for automated cell quantification and counting. Process How OncoMetastat® works. A closed-loop, extracorporeal process designed for gentle, continuous CTC depletion. Watch the OncoMetastat® workflow video. Know More 1 Blood Collection A clinical blood sample (1–10 ml) is collected via a standard BCT (Blood Collection Tube) and loaded into the cartridge through the aspirator needle system. 2 Spiral Channel Processing The peristaltic pump circulates blood through the 3D-printed spiral channel plate. The stage vibrator ensures continuous, uniform flow and prevents bead aggregation. 3 Affinity-Based CTC Capture EpCAM, Transferrin, and N-Cadherin conjugated glass beads selectively bind circulating tumor cells as blood passes through the bead matrix. 4 Effluent Return & Analysis Processed blood exits via the effluent line. Captured CTCs on the glass bead substrate are then stained and quantified using CK18/DAPI fluorescence imaging. Indication Scope Cancer types under evaluation. OncoMetastat® has been tested across a broad range of solid tumor types in clinical blood samples. Know More Breast Lung Colorectal Prostate Gall Bladder Liver Stomach Thyroid and more

Review the Actorius OncoMetastat's terms and conditions governing the use of our website, services, and information related to our oncology research and technologies. Terms & Conditions Date Updated: 31 May 2026 Welcome to the official website of OncoMetastat , a product of Actorius Innovations & Research Co. , accessible at [https://oncometastat.com ] (the “Website”). By accessing or using this Website, you agree to comply with and be bound by the following Terms and Conditions. Please review them carefully. 1. Acceptance of Terms By accessing, browsing, or using this Website, you acknowledge that you have read, understood, and agreed to be bound by these Terms and Conditions, along with our Privacy Policy. If you do not agree with any part of these terms, you must discontinue use of the Website immediately. 2. Use of the Website The content on this Website is provided for general informational and educational purposes only and is subject to change without prior notice. You agree to use this Website solely for lawful purposes and in a manner that does not infringe the rights of, restrict, or inhibit the use of this Website by any third party. Any unauthorised use, misuse, or abuse of this Website may give rise to a claim for damages and/or be a criminal offence under applicable Indian laws. 3. Intellectual Property Rights All content on this Website, including but not limited to the OncoDiscover brand, text, graphics, logos, icons, images, illustrations, videos, audio, software, design elements, and data compilations, is the property of Actorius Innovations & Research Pvt. Ltd. or its licensors and is protected by applicable Indian and international intellectual property laws. You may not copy, reproduce, modify, republish, upload, post, transmit, distribute, or exploit any content from this Website in any form or by any means without prior written permission from Actorius Innovations & Research Pvt. Ltd. 4. Third-Party Links This Website may contain links to third-party websites or resources provided for convenience or informational purposes only. Such links do not constitute an endorsement, sponsorship, or recommendation by Actorius Innovations & Research Pvt. Ltd. or OncoDiscover. We have no control over the content, policies, or practices of third-party websites and accept no responsibility or liability for any loss or damage arising from your use of such websites. 5. Disclaimer of Warranties and Limitation of Liability This Website and its content are provided on an “as is” and “as available” basis. Actorius Innovations & Research Pvt. Ltd. makes no representations or warranties, express or implied, regarding the accuracy, completeness, reliability, suitability, or availability of the OncoDiscover Website or its content. To the fullest extent permitted by law, Actorius Innovations & Research Pvt. Ltd. shall not be liable for any direct, indirect, incidental, special, consequential, or exemplary damages, including but not limited to loss of profits, data, goodwill, or other intangible losses, arising out of or in connection with your use of, or inability to use, the Website. Nothing in these Terms shall exclude or limit any liability that cannot be excluded under applicable Indian law. 6. Indemnification You agree to indemnify, defend, and hold harmless Actorius Innovations & Research Pvt. Ltd., its directors, officers, employees, affiliates, partners, agents, and licensors from and against any claims, liabilities, damages, losses, costs, or expenses (including reasonable legal fees) arising from: Your use or misuse of the Website Your violation of these Terms and Conditions Your infringement of any intellectual property or other rights of any third party 7. Governing Law and Jurisdiction These Terms and Conditions shall be governed by and construed in accordance with the laws of India. You agree that any disputes arising out of or relating to these Terms or the use of the Website shall be subject to the exclusive jurisdiction of the courts located in [India – Pune, Maharashtra]. 8. Modifications to Terms Actorius Innovations & Research Pvt. Ltd. reserves the right to revise, modify, or update these Terms and Conditions at any time without prior notice. Any changes will be effective immediately upon posting on the Website. Your continued use of the Website after such changes constitutes acceptance of the revised Terms. 9. Services, Refunds, and Cancellations Where applicable, OncoDiscover services offered by Actorius Innovations & Research Pvt. Ltd., including research, diagnostics, analytics, or related scientific and healthcare solutions, are subject to specific terms communicated at the time of engagement. Due to the specialized and scientific nature of our offerings, refunds or cancellations may be limited or not permitted once a service has commenced, data has been processed, or samples/materials have been analyzed. Any requests for cancellation or refund, where applicable, must be submitted in writing through our official communication channels and will be evaluated on a case-by-case basis. 10. Contact Information If you have any questions, concerns, or requests regarding these Terms and Conditions, please contact us at: OncoDiscover (A product of Actorius Innovations & Research Pvt. Ltd.) Website: https://actorius.com/contact Email: info@actorius.com

Discover how circulating tumor cells (CTCs) drive metastasis and why targeting them is critical for controlling cancer progression. Circulating Tumor Cells Fugitives on the run What are Circulating Tumor Cells? Circulating Tumor Cells (CTC) are cells that are shed into the bloodstream by the primary tumor. CTCs have been investigated as diagnostic, prognostic and predictive biomarkers in many types of cancer. CTC serve as seeds for growth of additional tumors (metastasis) in vital distant organs. CTC counts are associated with unfavorable prognosis in early stage cancer patients. What is Circulating Tumor Cell Clusters? CTC clusters are defined as groups of two or more aggregated CTCs found in the blood of patients with solid tumor. CTC clusters have a survival advantage over individual CTCs during their transit in the blood stream and a better potential for colonization in the distant sites and can likely contribute to metastasis. Cancer lurks in shadow. Let’s discover it early. Know More The OncoMetastat® is designed to delay cancer metastasis in early stage cancers. 01 Early Detection of Cancer. Early diagnosis = Better prognosis It is widely accepted that early detection of cancer is key to ensure a better outcome of cancer therapy for patients. But usually the earliest indication of cancer is due to symptoms (bleeding, lumps, non-healing wound etc) rather than the result of proactive testing. Since these symptoms are at many times improperly diagnosed or ignored, many patients are diagnosed with cancer only at a later stage. This makes treatment and recovery difficult for the patient. Cancer metastasis accounts for 90% of cancer deaths in comparison to deaths due to primary tumor. Thus, it is critical to know at the earliest possible stage about presence or spread of cancer. In a normal ‘healthy’ human being or in a person detected with possible cancer symptoms, the OncoDiscover® CTC Test can be used to identify presence of cancer and the extent of cancer metastasis. This will ensure that awareness of cancer presence is at the earliest possible stage and may result in better outcome during treatment. 02 Detection of Cancer Relapse Conventional tests have limited sensitivity or are difficult to perform on a regular basis to track the recurrence of cancer. It is widely accepted that early detection of cancer is key to ensure a better outcome of cancer therapy for patients. But usually the earliest indication of cancer is due to symptoms (bleeding, lumps, non-healing wound etc) rather than the result of proactive testing. Since these symptoms are at many times improperly diagnosed or ignored, many patients are diagnosed with cancer only at a later stage. This makes treatment and recovery difficult for the patient. Cancer metastasis accounts for 90% of cancer deaths in comparison to deaths due to primary tumor. Thus, it is critical to know at the earliest possible stage about presence or spread of cancer. In a normal ‘healthy’ human being or in a person detected with possible cancer symptoms, the OncoDiscover® CTC Test can be used to identify presence of cancer and the extent of cancer metastasis. This will ensure that awareness of cancer presence is at the earliest possible stage and may result in better outcome during treatment. 03 Monitoring of cancer therapy. Many patients are intolerant to the PET/CT and cannot undergo the scan multiple times. It is widely accepted that early detection of cancer is key to ensure a better outcome of cancer therapy for patients. But usually the earliest indication of cancer is due to symptoms (bleeding, lumps, non-healing wound etc) rather than the result of proactive testing. Since these symptoms are at many times improperly diagnosed or ignored, many patients are diagnosed with cancer only at a later stage. This makes treatment and recovery difficult for the patient. Cancer metastasis accounts for 90% of cancer deaths in comparison to deaths due to primary tumor. Thus, it is critical to know at the earliest possible stage about presence or spread of cancer. In a normal ‘healthy’ human being or in a person detected with possible cancer symptoms, the OncoDiscover® CTC Test can be used to identify presence of cancer and the extent of cancer metastasis. This will ensure that awareness of cancer presence is at the earliest possible stage and may result in better outcome during treatment.

Read the Actorius OncoMetastat's privacy policy to understand how we collect, use, and protect personal information across our website and services. Privacy Policy Date Updated: 31 May 2026 Actorius Innovations and Research Co. (“we,” “us,” or “our”), the creators of OncoMetastat , is committed to protecting your privacy. This Privacy Policy explains how we collect, use, disclose, and safeguard your personal information when you access or use the OncoDiscover website at [https://www.oncometastat.com ] (“Site”), in accordance with applicable Indian data protection laws, including the Information Technology Act, 2000 and the rules made thereunder. 1. Information We Collect We collect the following categories of information through our Site: a. Personal Information Information that may identify you and is voluntarily provided by you, including but not limited to: Full Name Email Address Phone Number (optional) Organization or Company Name (optional) Professional details you choose to share Any other information you voluntarily submit via contact forms or inquiries b. Usage Data Information automatically collected when you interact with our Site, such as: IP address Browser type and version Operating system Pages visited and time spent on the Site Referring and exit URLs Device identifiers Approximate location data (where permitted and with consent) 2. How We Use Your Information We use the information we collect to: Operate, maintain, and improve our Site Personalize and enhance your browsing experience Understand user behavior and site performance Respond to inquiries and provide requested information Communicate updates, insights, or promotional material (only with your consent) Ensure site security and prevent misuse or fraudulent activity Comply with applicable legal and regulatory obligations Note: Your personal information will only be used for purposes consistent with this Privacy Policy. 3. Sharing of Information We do not sell, rent, or trade your personal information. We may share information only in the following situations: With trusted service providers who assist us in operating our Site (e.g., hosting, analytics), subject to confidentiality obligations. When required by law, regulation, court order, or governmental authority. To protect the rights, safety, or property of Actorius Innovations & Research Pvt. Ltd., OncoDiscover, our users, or others. In connection with investigations of potential violations of our terms or applicable laws. 4. Cookies and Tracking Technologies We use cookies and similar technologies to: Remember user preferences Analyze traffic and site usage Improve performance and functionality Deliver relevant content (where consent is provided) You may manage or disable cookies through your browser settings. Please note that disabling cookies may affect certain features of the Site. 5. Data Security We implement reasonable administrative, technical, and physical safeguards to protect your personal information from unauthorized access, disclosure, or misuse. While we strive to protect your data, no method of transmission over the internet or electronic storage is completely secure, and absolute security cannot be guaranteed. 6. Your Rights Subject to applicable Indian laws, you may have the right to: Access the personal data we hold about you Request correction of inaccurate or incomplete data Request deletion of your personal data, subject to legal requirements Restrict or object to certain processing activities Withdraw consent where processing is based on consent To exercise these rights, please contact us using the details provided in Section 9. 7. Children’s Privacy The Site is not intended for use by individuals under the age of 18. We do not knowingly collect personal data from minors. If we become aware that a minor has provided personal information, we will take steps to delete such data promptly. 8. Changes to This Privacy Policy We may update this Privacy Policy from time to time to reflect changes in legal, regulatory, or operational requirements. Any updates will be posted on this page with a revised “Last Updated” date. We encourage you to review this policy periodically. 9. Contact Us If you have any questions, concerns, or requests regarding this Privacy Policy, please contact us at: Website: [ https://www.actorius.in/contact ] Email: [info@actorius.com ]

Explore scientific publications focused on circulating tumor cells, metastasis biology, and emerging strategies for cancer control. Publications Research That Shapes the Future of Oncology Access studies, scientific papers, and published findings advancing cancer diagnostics and care. 1 Sept 2026 Longitudinal Assessment of Circulating Tumor Cells Expressing PD-L1 and Clusters in Esophageal Cancer Patients A longitudinal study of 110 esophageal cancer patients evaluated CTCs, PD-L1 expression, and CTC clusters, highlighting their potential as predictive biomarkers for treatment outcomes and occult minimal cellular residual disease. Read More 30 Aug 2026 Detection of Androgen Receptor Splice Variant 7 in Circulating Tumor Cells for Dynamic Treatment Decision in Prostate Cancer Patients This study evaluated AR-V7 in CTCs and clusters from prostate cancer patients, highlighting its potential to predict ARSI resistance and support dynamic treatment decisions. Read More 30 Aug 2026 Algorithm based analysis of circulating tumour cells in cancer patients A study evaluating CellMatrics, a Python-based automated image analysis algorithm for CTC detection, demonstrated rapid and robust concordance with manual CTC analysis across blood samples from 32 cancer patients. Read More 30 Aug 2026 Assessment of apprehension for Minimal Cellular Residual Disease Using Circulating Tumour Cells in Pre and Post Surgery Breast Cancer Patients A prospective study evaluates RUPIKA, a structured CTC-based MRD disclosure protocol, showing significantly reduced cancer worry among breast cancer patients after surgery compared with routine result communication. Read More 30 Aug 2026 Capture of Epithelial-Mesenchymal Transitioning Circulating Tumor Cells using Affinity Based N-Cadherin System A study demonstrating N-Cadherin affinity-based capture of EMT-associated CTCs in diverse cancers, with Vimentin-positive CTC detection in 90% of samples and N-Cadherin expression revealing heterogeneous metastatic phenotypes. Read More 30 Aug 2026 Capture of Cancerous Cells and Overall Survival in Rats using Ex-vivo Extracorporeal Device in Multiple Onco-dialysis Cycles An animal study evaluated OncoMetastat for ex-vivo cancer cell capture, safety, and survival in rats. Across multiple onco-dialysis cycles, cancer cells were captured, all test-group rats survived 14 days, and histopathology showed normal tissues. Read More 30 Aug 2026 Comparative Analysis of Circulating Tumor Cells, Clusters, and PD-L1 Expression in Paired Peripheral and Portal Venous Blood with Solid Malignancies A prospective study compares circulating tumor cells, CTC clusters, and PD-L1 expression in paired peripheral and portal venous blood, highlighting compartment-specific differences and the potential of dual-compartment liquid biopsy profiling. Read More 30 Aug 2026 Evaluation of circulating tumor cells expressing PD-L1 and CTC clusters at baseline and follow ups in triple-negative breast cancer A retrospective study of 180 TNBC blood samples evaluated CTC burden, PD-L1 expression and CTC clusters using the CDSCO-approved OncoDiscover platform, highlighting their potential for longitudinal disease monitoring and biomarker-guided management. Read More 17 Mar 2026 ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Read More 17 Mar 2026 ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Read More 17 Mar 2026 ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. Read More 17 Mar 2026 AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. Read More 17 Mar 2026 ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. Read More 17 Mar 2026 AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. Read More 7 Mar 2026 AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. Read More 3 Nov 2025 PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India. Read More 3 Nov 2025 Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. Read More 3 Nov 2025 Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Read More 3 Nov 2025 Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. Read More 17 Oct 2025 Circulating Biomarkers Reveal their Complementary Association in Primary and Metastatic Colorectal Cancer Patients Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients. Read More First Prev 1 Page 1 Next Last

Learn how cancer spreads through the body, the role of circulating tumor cells, and why controlling metastasis is critical in oncology. Circulating Tumor Cells Fugitives on the run What are Circulating Tumor Cells? Circulating Tumor Cells (CTC) are cells that are shed into the bloodstream by the primary tumor. CTCs have been investigated as diagnostic, prognostic and predictive biomarkers in many types of cancer. CTC serve as seeds for growth of additional tumors (metastasis) in vital distant organs. CTC counts are associated with unfavorable prognosis in early stage cancer patients. What is Circulating Tumor Cell Clusters? CTC clusters are defined as groups of two or more aggregated CTCs found in the blood of patients with solid tumor. CTC clusters have a survival advantage over individual CTCs during their transit in the blood stream and a better potential for colonization in the distant sites and can likely contribute to metastasis. TEDx Talk — Capturing cancer cells-Uncovering secrets for treatments by Aravindan Vasudevan – CEO, Actorius Date: February 28, 2023 TedxTalks Link Cell and Cellular Division The Cell is the basic building block of the human body and there are trillions of cells. Cells have the unique characteristic of replicating (or replicating themselves) via cell division and propagating to perform other critical functions for human survival. The cells also have a function which tells them when to stop dividing and undergo a process called Apoptosis (programmed cell death). This way the body clears the old cells and new cells every day. Tumor and Angiogenesis Due to various factors such as pollution, poor diet, smoking, radiation etc, some normal cells undergo mutation in a process known as carcinogenesis to become cancer cells . These cancer cells grow abnormally and indefinitely, subsequently congregating form a mass known as Tumor . These tumors survive by creating new blood vessels (for oxygen and nutrient supply) in a process known as Angiogenesis . Cancer Metastasis. The tumor is a mass of cancer cells from which some cells try to move away and invade the body via the circulatory system. These cells enter and circulate in the blood stream via a process known as Intravasation . These cells are known as Circulating Tumor Cells (CTC) . Circulating Tumor Cells (CTC) have the ability to also get out of the blood stream via Extravasation . Thus, cancers cells can travel from one tissue/organ to another and potentially form a new tumor in the invaded tissue/organ. This process is known as metastasis and it is responsible for 90% of cancer related deaths worldwide. Circulating Tumor Cells (CTC). Each gram of tumor tissue sheds upto 1 million cancer cells into the blood stream each day. These Circulating Tumor Cells (CTC) serve as seeds for growth of additional tumors (metastasis) in vital distal organs. There is a positive correlation between CTC number and the clinical status of the cancer. OncoDiscover® CTC Test allows for regular monitoring of disease progression and can serve as an early indicator for relapse.

Download detailed literature on OncoMetastat®, including its approach to capturing, intercepting, and reducing circulating tumor cells. Literature Product Resources Explore OncoMetastat® brochures, guides, and technical documents to learn more about the technology, science, and clinical applications behind our solutions. 9 Mar 2026 OncoMetastat Brochure Detailed Brochure for OncoMetastat Read More First Prev 1 Page 1 Next Last

Discover the Actorius Research Centre, where scientists advance cancer diagnostics, liquid biopsy technologies, and innovative oncology solutions. Research Centre We are in pursuit of identifying and developing life-saving solutions for global healthcare problems with a focus on cancer diagnostics and cure. Our story so far An innovation-driven organisation 11000+ Patients Served 100+ Scientists 100+ Publications 1000+ Patients Served Know more Mission, Vision & Purpose Innovating with Intent Our mission, vision, and purpose reflect our commitment to meaningful progress and measurable outcomes. Mission To develop innovative methodologies to develop diagnostic tests that provide early indicators of oncogenesis and enable informed treatment strategies. Vision To collectively advance and improve human health by developing biomedical innovations into practical applications that have wider reach, accessibility and affordability. Purpose To positively impact everyone, by developing solutions that have reduced time to decision making and providing precise information for a chosen course of action. Our Values What We Stand For Our values define our commitment to rigorous science, responsibility, and meaningful impact. Work on challenges with cutting-edge science and innovation. Work towards making it accessible and affordable to the masses. Ensure critical clinical validations for every outcome. Bio-materials with high specificity, efficiency and sensitivity. Scientific disciplines with interdisciplinary intelligence at the core. Take every little step to ensure cancer patient’s lives are saved. Detect cancer relapse early, when it can be cured. We are committed to bringing stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. Focused on creating novel cancer diagnostic tests. Know more Rigour in every action. Every product undergoes intense design and development. Leaving no stone unturned. We follow the most stringent quality norms like ISO13485 and regulatory requirements. Passionate and emphatic. We are committed to developing solutions for unmet medical needs. We build high-risk innovative products, which have a very long life-cycle, using novel biomaterials.